CytoMed Therapeutics (NASDAQ:GDTC) Rating Reiterated by Benchmark

Benchmark restated their speculative buy rating on shares of CytoMed Therapeutics (NASDAQ:GDTC) in a research note issued to investors on Thursday, Benzinga reports. They currently have a $5.00 target price on the stock.

CytoMed Therapeutics Price Performance

NASDAQ:GDTC traded down $0.11 during midday trading on Thursday, hitting $1.90. 1,227 shares of the stock were exchanged, compared to its average volume of 36,353. CytoMed Therapeutics has a one year low of $1.20 and a one year high of $5.50. The business has a 50-day moving average price of $1.64 and a two-hundred day moving average price of $1.92.

CytoMed Therapeutics Company Profile

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.